Smallwood Wealth Investment Management LLC Reduces Johnson & Johnson (NYSE:JNJ) Stake


Smallwood Wealth Investment Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating ) by 35.2% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,622 shares of the company’s stock after selling 1,965 shares during the quarter. Johnson & Johnson makes up about 0.6% of Smallwood Wealth Investment Management LLC’s holdings, making the stock its 29th largest position. Smallwood Wealth Investment Management LLC’s holdings in Johnson & Johnson were worth $642,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Winthrop Advisory Group LLC boosted its holdings in Johnson & Johnson by 3.7% during the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company’s stock valued at $1,611,000 after acquiring an additional 325 shares during the last quarter. Allied Investment Advisors LLC boosted its holdings in Johnson & Johnson by 8.2% in the first quarter. Allied Investment Advisors LLC now owns 47,721 shares of the company’s stock valued at $8,458,000 after acquiring an additional 3,635 shares during the last quarter. Five Oceans Advisors boosted its holdings in shares of Johnson & Johnson by 1.9% in the first quarter. Five Oceans Advisors now owns 4,384 shares of the company’s stock valued at $777,000 after buying an additional 83 shares in the last quarter. RB Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. RB Capital Management LLC now owns 9,626 shares of the company’s stock valued at $1,706,000 after buying an additional 169 shares in the last quarter. Finally, BLB&B Advisors LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the first quarter. BLB&B Advisors LLC now owns 131,323 shares of the company’s stock valued at $23,274,000 after buying an additional 486 shares in the last quarter. 68.78% of the shares are currently owned by hedge funds and other institutional investors.

In related news, insider William Haight sold 29,699 shares of the stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now owns 80,236 shares in the company, valued at $14,729,724.88. The transaction was disclosed in a document filed with the SEC, which is available via this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. Disclosure of this sale can be found here. Insiders have sold 78,161 shares of company stock worth $13,895,302 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

A number of analysts recently commented on the company. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $180.00 to $183.00 in a report on Wednesday, March 16th. Citigroup reduced their price objective on Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Raymond James boosted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Morgan Stanley boosted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $190.67, based on data from MarketBeat.com.

NYSE:JNJ opened at $178.28 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39, and a quick ratio of 1.14. The firm has a 50-day moving average of $176.89 and a 200-day moving average of $174.14. The stock has a market cap of $469.13 billion, a P/E ratio of 24.03, a PEG ratio of 3.53 and a beta of 0.63. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating ) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. The company had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company reported $2.59 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 annual dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and markets a variety of health care products worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

Featured stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Get news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.